| Literature DB >> 30281596 |
Momna Rubab1, Ramachandran Chellia1, Kandasamy Saravanakumar2, Suresh Mandava3, Imran Khan1, Charles Nkufi Tango1, Mohammad Shakhawat Hussain1, Eric Banan-Mwine Daliri1, Se-Hun Kim1, Sudha Rani Ramakrishnan4, Myeong-Hyeon Wang2, Jongkook Lee3, Joong-Ho Kwon4, Sangeeta Chandrashekar5, Deog-Hwan Oh1.
Abstract
This study aimed at investigating the antimicrobial activity of different solvent extracts of Chinese cabbage Brassica rapa subsp. pekinensis (BRARP) and their antioxidant and cytotoxicity properties. Of the different solvents extracts, the chloroform extracts (CE) were significantly inhibited the bacterial pathogens at minimum inhibitory concentration (MIC) of 16.5 mg.mL-1. Biochemical analysis revealed that total phenol (62.6 ± 0.05 mg GAE.g-1) and flavonoids (27.6 ± 0.04 mg QE.g-1) were higher in the extracts of BRARP, which resulted in enhanced antioxidant activity in CE. A total of eight dominant compounds were detected in the potent antimicrobial extract from BRARP based on GC-MS analysis. The molecular interactions study revealed that, among the screened compounds the 1,2-benzenedicarboxylic acid and 2,3-dicyanopropionamide interacted with the active site of pathogenicity and survival related protein with lipopolysaccharide (LpxC) with higer binding energy. This work concluded that the 1, 2-Benzenedicarboxylic acid and 2, 3-Dicyanopropionamide from BRARP was reported to be good non-cytotoxic and antioxidant antimicrobials against bacterial pathogens.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30281596 PMCID: PMC6169867 DOI: 10.1371/journal.pone.0203306
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Antimicrobial activity of different solvent extracts of BRARP.
| List of microorganisms | BRARP extracts (Conc. 33 mg.mL-1); Zone of inhibition (mm) | ||||||
|---|---|---|---|---|---|---|---|
| CE | TE | DE | EEE | EtE | ME | DWE | |
| 494 (Isolate) | 13.50 ± 0.03 | 15.00 ± 0.02 | 13.00 ± 0.05 | 13.10 ± 0.05 | - | - | - |
| ATCC 35150 | 14.50 ± 0.02 | 18.00 ± 0.01 | 12.50 ± 0.04d | 13.50 ± 0.05 | - | - | - |
| ATCC 43894 | 14.00 ± 0.02 | - | 12.00 ± 0.05 | 12.50 ± 0.03 | - | - | - |
| ATCC 13150 | 12.50 ± 0.05 | 12.00 ± 0.03 | 10.00 ± 0.03 | 10.00 ± 0.02 | - | - | - |
| KCTC 21004 | 10.60 ± 0.02 | - | 10.60 ± 0.05 | - | - | - | - |
| KCTC 3545 | 11.60 ± 0.02 | - | - | 10.60 ± 0.04 | - | - | - |
| KCTC 13302 | 12.30 ± 0.03 | - | 10.00 ± 0.06 | 10.30 ± 0.02 | - | - | - |
| KCTC 7965 | 13.60 ± 0.05 | - | 11.30 ± 0.03 | 10.30 ± 0.03 | - | - | - |
| KCTC 6145 | 09.80 ± 0.02 | - | - | 08.50 ± 0.04 | - | - | - |
| KCTC 6143 | - | - | - | - | - | - | - |
| KCTC 6317 | 13.60± 0.02 | - | 10.60± 0.05 | - | - | - | - |
-: not active, CE: Chloroform Extract, TE: Toluene Extract, DE: Dichloromethane Extract, EEE: Ethyl Ether Extract, EtE: Ethanol Extract, ME: Methanol Extract, DWE: Distilled Water Extract
a: more sensitive
b: moderate sensitive
c: less sensitive, MHA-Muller Hinton Agar, MRS-De Man, Rogosa and Sharpe agar
Thermostability of chloroform extract of BRARP.
| List of | Chloroform extract at 95°C at different time periods (Min); Zone of inhibition (mm) | |||||
|---|---|---|---|---|---|---|
| 5 | 15 | 30 | 45 | 60 | 90 | |
| 494 (Isolate) | 11.00 ± 0.01 | 11.00 ± 0.03 | 10.50 ± 0.05 | 12.00 ± 0.01 | 11.00 ± 0.04 | 11.00 ± 0.03 |
| ATCC 35150 | 13.00 ± 0.02 | 12.00 ± 0.01 | 11.00 ± 0.03 | 13.00 ± 0.02 | 10.00 ± 0.03d | 12.00 ± 0.01 |
| ATCC 43894 | 12.00 ± 0.02 | 14.00 ± 0.03 | 10.00 ± 0.03 | 12.00 ± 0.02 | 12.00 ± 0.05 | 14.00 ± 0.03 |
| ATCC 13150 | 10.50 ± 0.01 | 09.50 ± 0.03 | 08.00 ± 0.02d | 10.50 ± 0.01 | 09.00 ± 0.05 | 09.50 ± 0.03 |
| KCTC 21004 | 10.00 ± 0.02 | 09.00 ± 0.03 | 09.00 ± 0.01 | 10.00 ± 0.02 | 09.00 ± 0.03 | 09.00 ± 0.03 |
| KCTC 3545 | 10.00 ± 0.02 | 10.30 ± 0.05 | 10.00 ± 0.02 | 10.00 ± 0.02 | 10.00 ± 0.03 | 10.30 ± 0.05 |
| KCTC 13302 | 10.00± 0.02 | 09.00± 0.03 | 10.00± 0.03 | 10.00 ± 0.02 | 10.00± 0.05 | 09.00 ± 0.03 |
| KCTC 7965 | 10.00 ± 0.03 | 09.00 ± 0.01 | 10.00 ± 0.03 | 10.00 ± 0.03 | 10.00 ± 0.04 | 09.00 ± 0.01 |
| KCTC 6145 | 09.00 ± 0.02 | 08.00 ± 0.03 | 08.30 ± 0.03 | 09.00 ± 0.02 | 09.00 ± 0.03 | 08.00 ± 0.03 |
| KCTC 6143 | - | - | - | - | - | - |
| KCTC 6317 | 12.30 ± 0.02 | 12.30 ± 0.03 | 12.00 ± 0.01 | 12.30 ± 0.02 | 12.00 ± 0.04 | 12.30 ± 0.03 |
-: not active
a: more sensitive
b: moderate sensitive
c: less sensitive, MHA-Muller Hinton Agar, MRS-De Man, Rogosa and Sharpe agar
Fig 1Determination of minimum inhibitory concentration based on growth curve assay of BRARP crude extract, 1a: ATCC 35150, and 1b: ATCC 13150, TSB: Tryptic Soy Broth.
Fig 2Antioxidant activity of different extracts of BRARP, (a) DPPH and (b) ABTS assay.
Fig 3HPTLC chromatogram of phenolic acid fractions from BRARP migration distance: 40 mm; application volume, polyethylene glycol reagent (NP/PEG) (Fluka Chemie, Switzerland).
UV254 nm light detection; (c) UV365 nm light detection. Bands (B): 1, Phenol. Lanes (L): 2. Chloroform extract BRARP of (33 mg.mL-1); 3. Chloroform extract of BRARP (16.5 mg.mL-1).
Cytotoxic activity of BRARP in different solventsagainst MCF -7 cell line.
| IC50 (μg.mL-1) | ||
|---|---|---|
| MCF-7 | ||
| 1 | >50 | |
| 2 | >50 | |
| 3 | >50 | |
| 4 | >50 | |
| 5 | >50 | |
| 6 | >50 | |
| 7 | Tamoxifen | 10.58 |
-: *EEE: Ethyl ether Extract
**TE: Toluene Extract
***EtE: Ethanol Extract
****ME: Methanol Extract
*****CE: Chloroform Extract
******DE: Dichloromethane Extract, IC: Half maximal inhibitory concentration, MCF: Michigan Cancer Foundation-7 (Brest cancer cell line)
Molecular docking score of identified metabolites from chloroform and methanol extract of BRARP.
| Name of the compound | Chemical formula | Molecular weight (Da) | Area (%) | Docking score (Kcal.mol-1) | Activity | References |
|---|---|---|---|---|---|---|
| (E)-2-Butenoic acid propyl ester | C7H12O2 | 128.169 | 0.05 | -4 | ACE, Angiotensin-converting enzyme | [ |
| Phenol | C6H6O | 94.111 | 0.05 | -4.5 | Antimicrobial | [ |
| Sodium phenoxide | C6H5NaO | 116.093 | 0.06 | -4.1 | ||
| 4-Pyridinecarboxylic acid | C6H5NO2 | 123.109 | 0.05 | -4.6 | Anticancer (oral), Antidote, Orexigen | [ |
| s-Triazolo[4,3-a]pyridine | C6H5N3 | 119.124 | 0.02 | -4.6 | Antimicrobial | [ |
| 1,2-Benzenedicarboxylic acid | C8H6O4 | 166.131 | 0.01 | -5.8 | Antimicrobial, antioxidant | [ |
| 2,2-Dimethoxybutane | C6H14O2 | 118.174 | 0.04 | -3.5 | Antimicrobial, | [ |
| 2,3-Dicyanopropionamide | C5H5N3O | 123.113 | 1.19 | -4.8 | Antimicrobial | [ |
Fig 4Predicted binding mode complex of molecular model (a) 1,2-Benzenedicarboxylic acid and LpxC complex, (b) 2,3-Dicyanopropionamide and LpxC complex.
Fig 5Adhered of dead/live cells Confocal Microscopic imaging of ATCC 35150 and ATCC 13150 in which observed green spots (Syto-9) healthy live cells and red spots (Propidium Iodide) dead cells (20X magnification). (a, h) optical microscopic observation; (b, d, f) untreated ATCC 35150; (c) ATCC 35150 treated with Novobiocin; (e) ATCC 35150 treated with BRARP extract; (g) ATCC 35150 treated with 1, 2-Benzenedicarboxylic acid 1.0 mg.mL-1; (I, k, m) untreated of ATCC 13150; (j) ATCC 13150 treated with Novobiocin, (l) ATCC 13150 treated with BRARP extract; (n) ATCC 13150 treated with 1, 2-Benzenedicarboxylic acid 1.0 mg.mL-1.